PBM Capital

PBM Capital, founded by entrepreneur Paul Manning in 2010, is a dynamic healthcare-focused investment firm with a strong emphasis on pharmaceuticals, biotechnology, and life sciences. Headquartered in Charlottesville, Virginia, with an additional office in New York, PBM partners with scientists and innovators to create groundbreaking therapies that significantly improve patient outcomes. Their team provides capital along with critical operational and strategic expertise, helping companies navigate complex healthcare markets and scale rapidly. PBM’s portfolio boasts several notable successes, including AveXis, which was acquired by Novartis for $8.7 billion, and Dova Pharmaceuticals, which completed an IPO before being acquired by Swedish Orphan Biovitrum. The firm seeks out companies with revolutionary science and strong leadership, focusing on areas such as gene therapy, biologics, and drug development. PBM takes an active role in guiding its investments, offering not only funding but also leveraging its extensive network to accelerate commercialization. Their investment strategy centers around long-term value creation, seeking out companies with life-changing technologies and the potential to transform healthcare. By combining operational experience with capital investment, PBM aims to help founders bring revolutionary therapies to market and create lasting impact​.